A Singular Vision
Relentless pursuit of transformative therapies targeting FcRn, a central mediator in autoimmune responses.
Rapid clinical advancement across multiple indications for our lead investigational candidate SYNT001.
FcRn plays a central role across a wide swath of autoimmune diseases affecting millions of people worldwide.
NEWS & PROGRESS
SEPTEMBER 12, 2018
Syntimmune Announces FDA Orphan Drug Designation for SYNT001 in Treatment of Pemphigus
@syntimmune | SEPTEMBER 21, 2018
Our scientists played pivotal roles in advancing understanding of the complex role of FcRn in IgG-mediated autoimmu… https://t.co/MsuJR9LzYf